Table
1: Baseline
characteristics of the 124 Type 2 diabetes patients included, compared to 377
patients, who did not consent to CGM.
|
Patients
included N
= 124 |
Patients
that did not consent to CGM N = 377 |
Age |
58 (11) |
61 (12)* |
Sex
(% female) |
46 % |
38% |
Ethnicity (% caucasian) |
90 % |
85% |
BMI |
32 (6) |
31 (6) |
HbA1c (mmol/mol) |
58 (18) |
58 (14) |
Duration of DM (years) |
11 (8) |
13 (10)* |
Blood pressure (MAP in mmHg) |
98 (10) |
97 (12) |
Current smoking |
20 % |
16% |
Use of antidepressant drugs |
6% |
9% |
Complications
|
|
|
- microvascular |
|
|
- neuropathy |
26 % |
30% |
- retinopathy |
20 % |
25% |
- nephropathy |
19 % |
20% |
- macrovascular |
32 % |
38% |
Therapy |
|
|
-
None |
5 % |
5% |
-
Oral agents only/ GLP-1 analoga |
40 % |
39% |
-
Insulin |
55 % |
56% |
o
Long-acting |
6 % |
6% |
o
Premix |
4 % |
8% |
o
Intensive |
38 % |
35% |
o
CSII |
7 % |
7% |
Glycaemic variability (SD) |
2.2 (1.0) |
Not determined |
Questionnaires |
|
|
PAID |
12.5 (0-75) |
7.5 (0-67.5)* |
SF-12 Physical component score Mental component score |
39 (11) 46 (10) |
41 (11) 48 (10)* |
EQ5D VAS
score Index Value |
64 (18) 0.78 (-0.13 – 1.00) |
65 (19) 0.81 (-0.26 - 1.00) |
Results are described as mean (SD) or median (range)
or percentage
HbA1c 58 mmol/mol equals 7.5%
Neuropathy is defined as a score on the neurothesiometer of > 25 V
Retinopathy is defined as any degree of retinopathy
(as assessed by fundus photographs)
Nephropathy is defined as GFR (MDRD) < 60
Macro-vascular complication is defined as a composite
endpoint (MI or CVA or angioplasty or vascular surgery (coronary, carotid,
femoral, iliacal, aortal)
Antidepressants drugs were defined as drugs that are
indicated for depression, however drugs commonly prescribed for neuropathic
pain were excluded (amitriptyline, duloxetine, nortrilen)
*Significant difference (p <
0.05)